SPAR, a lncRNA encoded mTORC1 inhibitor.
Matsumoto, Akinobu, John G Clohessy, and Pier Paolo Pandolfi. 2017. “SPAR, a LncRNA Encoded MTORC1 Inhibitor.”. Cell Cycle (Georgetown, Tex.) 16 (9): 815-16.
Search
Search results
56 results found
The pleiotropic role of non-coding genes in development and cancer.
Pasut, Alessandra, Akinobu Matsumoto, John G Clohessy, and Pier Paolo Pandolfi. 2016. “The Pleiotropic Role of Non-Coding Genes in Development and Cancer.”. Current Opinion in Cell Biology 43: 104-13.
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.
Rau, Rachel, Daniel Magoon, Sarah Greenblatt, Li Li, Colleen Annesley, Amy S Duffield, David Huso, et al. 2014. “NPMc+ Cooperates With Flt3/ITD Mutations to Cause Acute Leukemia Recapitulating Human Disease.”. Experimental Hematology 42 (2): 101-13.e5.
The RNA binding protein ESRP1 fine-tunes the expression of pluripotency-related factors in mouse embryonic stem cells.
Fagoonee, Sharmila, Claudia Bearzi, Ferdinando Di Cunto, John G Clohessy, Roberto Rizzi, Markus Reschke, Emanuela Tolosano, et al. 2013. “The RNA Binding Protein ESRP1 Fine-Tunes the Expression of Pluripotency-Related Factors in Mouse Embryonic Stem Cells.”. PloS One 8 (8): e72300.
Subtle variations in Pten dose determine cancer susceptibility.
Alimonti, Andrea, Arkaitz Carracedo, John G Clohessy, Lloyd C Trotman, Caterina Nardella, Ainara Egia, Leonardo Salmena, et al. 2010. “Subtle Variations in Pten Dose Determine Cancer Susceptibility.”. Nature Genetics 42 (5): 454-8.
Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer.
Montanaro, L, M Brigotti, J Clohessy, S Barbieri, C Ceccarelli, D Santini, M Taffurelli, et al. 2006. “Dyskerin Expression Influences the Level of Ribosomal RNA Pseudo-Uridylation and Telomerase RNA Component in Human Breast Cancer.”. The Journal of Pathology 210 (1): 10-8.